Clinical trial · Interventional
Pemetrexed and Carboplatin in Locally Advanced or Metastatic Breast Cancer
A Phase II Study of Alimta and Carboplatin in the Treatment of Patients With Locally Advanced or Metastatic Breast Cancer
NCT00072865CI-TRIAL-00000587completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a nonrandomized study of pemetrexed plus carboplatin, with the primary objective of determining the efficacy of the combination in tumor reduction, in patients with locally advanced or metastatic breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Neoplasm Metastasis | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Carboplatin | Drug | Carboplatin | ALIAS |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- antitumor activity
Secondary outcomes (1)
- measure
- duration of response;time to progressive disease;time to treatment failure
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologic or cytologic diagnosis of locally advanced or metastatic breast cancer * No prior chemotherapy for locally advanced or metastatic breast disease. * Patient may have received prior adjuvant therapy finished greater than 1 year prior to enrollment. * Adequate bone marrow, liver and kidney function * RECIST criteria for disease status Exclusion Criteria: * Prior treatment with pemetrexed * Pregnant or breast feeding * Brain Metastasis * unable or unwilling to take folic acid, vitamin B12 supplementation, or dexamethasone.
References
Publications (0)
Data not yet available
No reference posted for this study.